Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.
Center for Clinical and Translational Research, Seattle Children's Research Institute, Seattle, Washington.
Neuro Oncol. 2019 Jan 1;21(1):83-94. doi: 10.1093/neuonc/noy145.
Diffuse intrinsic pontine glioma (DIPG) is a uniformly fatal CNS tumor diagnosed in 300 American children per year. Radiation is the only effective treatment and extends overall survival to a median of 11 months. Due to its location in the brainstem, DIPG cannot be surgically resected. Immunotherapy has the ability to target tumor cells specifically; however, little is known about the tumor microenvironment in DIPGs. We sought to characterize infiltrating immune cells and immunosuppressive factor expression in pediatric low- and high-grade gliomas and DIPG.
Tumor microarrays were stained for infiltrating immune cells. RNA was isolated from snap-frozen tumor tissue and Nanostring analysis performed. DIPG and glioblastoma cells were co-cultured with healthy donor macrophages, T cells, or natural killer (NK) cells, and flow cytometry and cytotoxicity assays performed to characterize the phenotype and function, respectively, of the immune cells.
DIPG tumors do not have increased macrophage or T-cell infiltration relative to nontumor control, nor do they overexpress immunosuppressive factors such as programmed death ligand 1 and/or transforming growth factor β1. H3.3-K27M DIPG cells do not repolarize macrophages, but are not effectively targeted by activated allogeneic T cells. NK cells lysed all DIPG cultures.
DIPG tumors have neither a highly immunosuppressive nor inflammatory microenvironment. Therefore, major considerations for the development of immunotherapy will be the recruitment, activation, and retention of tumor-specific effector immune cells.
弥漫性内在脑桥神经胶质瘤(DIPG)是一种每年在美国诊断出 300 名儿童的致命中枢神经系统肿瘤。放射治疗是唯一有效的治疗方法,可将总生存期延长至中位数 11 个月。由于其位于脑干,DIPG 无法进行手术切除。免疫疗法具有特异性靶向肿瘤细胞的能力;然而,对于 DIPG 中的肿瘤微环境知之甚少。我们试图描述小儿低级别和高级别神经胶质瘤和 DIPG 中浸润性免疫细胞和免疫抑制因子的表达。
对肿瘤微阵列进行浸润性免疫细胞染色。从速冻肿瘤组织中分离 RNA,并进行 Nanostring 分析。将 DIPG 和胶质母细胞瘤细胞与健康供体巨噬细胞、T 细胞或自然杀伤(NK)细胞共培养,并进行流式细胞术和细胞毒性测定,分别表征免疫细胞的表型和功能。
与非肿瘤对照相比,DIPG 肿瘤中巨噬细胞或 T 细胞浸润没有增加,也没有过度表达程序性死亡配体 1 和/或转化生长因子β1 等免疫抑制因子。H3.3-K27M DIPG 细胞不会使巨噬细胞重新极化,但不会被激活的同种异体 T 细胞有效靶向。NK 细胞溶解了所有 DIPG 培养物。
DIPG 肿瘤既没有高度免疫抑制也没有炎症性微环境。因此,免疫疗法的主要考虑因素将是招募、激活和保留肿瘤特异性效应免疫细胞。